WoodTrust Financial Corp Has $1.85 Million Position in DexCom, Inc. $DXCM

WoodTrust Financial Corp lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,200 shares of the medical device company’s stock after purchasing an additional 300 shares during the quarter. WoodTrust Financial Corp’s holdings in DexCom were worth $1,851,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Horizon Investments LLC raised its holdings in DexCom by 2.2% in the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock valued at $383,000 after acquiring an additional 123 shares in the last quarter. Wedbush Securities Inc. grew its position in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company’s stock worth $899,000 after acquiring an additional 157 shares during the last quarter. Argonautica Private Wealth Management Inc. grew its position in DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company’s stock worth $407,000 after acquiring an additional 182 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its position in DexCom by 3.2% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after acquiring an additional 187 shares during the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 0.5%

NASDAQ:DXCM opened at $66.03 on Wednesday. The company has a market cap of $25.89 billion, a P/E ratio of 45.85, a P/E/G ratio of 1.39 and a beta of 1.47. The stock’s fifty day moving average price is $75.38 and its two-hundred day moving average price is $77.80. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. This trade represents a 1.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. UBS Group boosted their price objective on DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a report on Saturday, September 27th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $106.00 target price on shares of DexCom in a report on Monday, September 29th. Finally, Raymond James Financial increased their price objective on DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a report on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.42.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.